Carcinoma, Renal Cell
Showing NaN - NaN of 25
Carcinoma, Renal Cell Trial in Worldwide (Atezolizumab, Cabozantinib)
Active, not recruiting
- Carcinoma, Renal Cell
-
Tucson, Arizona
- +147 more
Jan 24, 2023
Carcinoma, Carcinoma, Renal Cell, Kidney Tumors Trial in Worldwide (Savolitinib, Sunitinib)
Active, not recruiting
- Carcinoma
- +7 more
-
La Jolla, California
- +58 more
Jan 13, 2023
Carcinoma, Renal Cell Trial in Worldwide (Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab)
Recruiting
- Carcinoma, Renal Cell
- Pembrolizumab
- +3 more
-
Birmingham, Alabama
- +229 more
Aug 11, 2022
Carcinoma, Renal Cell Trial in Worldwide (tivozanib HCl, Sorafenib)
Completed
- Carcinoma, Renal Cell
- tivozanib hydrochloride
- Sorafenib
-
Phoenix, Arizona
- +190 more
Jan 18, 2022
Carcinoma, Renal Cell Trial in Worldwide (Pazopanib, Sunitinib)
Completed
- Carcinoma, Renal Cell
-
Huntsville, Alabama
- +226 more
Apr 19, 2021
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (PF-05082566, rituximab)
Completed
- Lymphoma, Non-Hodgkin
- +6 more
-
Duarte, California
- +41 more
Mar 4, 2020
NSCLC, Carcinoma, Renal Cell, Breast Tumors Trial in United States (SGN-2FF, pembrolizumab)
Terminated
- Carcinoma, Non-Small-Cell Lung
- +7 more
-
Birmingham, Alabama
- +10 more
Jul 17, 2019
Carcinoma, Renal Cell, Kidney Diseases, Kidney Tumors Trial in United States (Combination of Varlilumab and Atezolizumab)
Terminated
- Carcinoma, Renal Cell
- +13 more
- Combination of Varlilumab and Atezolizumab
-
San Francisco, California
- +3 more
Apr 26, 2018
Carcinoma, Renal Cell Trial in United States (foretinib (formerly GSK1363089 or XL880))
Completed
- Carcinoma, Renal Cell
- foretinib (formerly GSK1363089 or XL880)
-
Greenbrae, California
- +11 more
Nov 8, 2017
Carcinoma, Renal Cell Trial in Los Angeles, Boston, Cleveland (Allogeneic DCs and Autologous RCC Tumor Derived Cells)
Completed
- Carcinoma, Renal Cell
- Allogeneic DCs and Autologous RCC Tumor Derived Cells
-
Los Angeles, California
- +3 more
Mar 4, 2015
Carcinoma, Renal Cell Trial in Canada, United States (Sorafenib (Nexavar, BAY43-9006))
Completed
- Carcinoma, Renal Cell
- Sorafenib (Nexavar, BAY43-9006)
-
Bessemer, Alabama
- +319 more
Aug 5, 2014
Carcinoma, Renal Cell Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Placebo)
Completed
- Carcinoma, Renal Cell
- Sorafenib (Nexavar, BAY43-9006)
- Placebo
-
Tucson, Arizona
- +120 more
Jan 8, 2014
Carcinoma, Renal Cell Trial in Boston (Nexavar (Sorafenib, BAY43-9006), Placebo)
Terminated
- Carcinoma, Renal Cell
- Nexavar (Sorafenib, BAY43-9006)
- Placebo
-
Boston, Massachusetts(unnamed)
Oct 10, 2013
Carcinoma, Renal Cell, Kidney Tumors Trial in Worldwide (Interferon Alfa, CCI-779, Interferon Alfa and CCI-779)
Completed
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Interferon Alfa
- +2 more
-
Little Rock, Arkansas
- +153 more
Sep 24, 2012
Update 5-Year Survival Of Subjects Who Participated In Axitinib
Completed
- Carcinoma, Renal Cell
- axitinib: observational study
-
San Francisco, California
- +7 more
Apr 18, 2012
Carcinoma, Renal Cell Trial in Worldwide (Interferon-alfa, SU011248)
Completed
- Carcinoma, Renal Cell
-
Jonesboro, Arkansas
- +123 more
Jan 19, 2010